ACE Report Cover
Oral Tramadol/Dexketoprofen & Injectable Paracetamol + Tramadol: A Meta-Analysis
Language
Download
Cite
+ Favorites
Language
Download
Cite
+ Favorites
AceReport Image
ARTHROPLASTY
Oral Tramadol/Dexketoprofen & Injectable Paracetamol + Tramadol: A Meta-Analysis .

Pain management after total hip arthroplasty: comparative study of analgesic efficacy and tolerability between oral tramadol/dexketoprofen and injectable paracetamol + tramadol.

Hip Int . 2024 May;34(3):304-310.

320 patients with primary hip osteoarthritis undergoing total hip arthroplasty were randomized to receive either oral tramadol/dexketoprofen (Group A, n=188) or intravenous paracetamol plus tramadol (Group B, n=135). The primary outcome of interest was the reduction in pain intensity measured by the visual analogue scale (VAS) over 48 hours postoperatively. Secondary outcomes included the need for rescue medication, safety profiles, and the percentage of responders (patients achieving at least 30% pain reduction). Outcomes were assessed at 2, 8, 24, 48 hours, and at 2 weeks postoperatively. Overall, the study revealed that patients receiving tramadol/dexketoprofen had a significantly faster and greater reduction in pain, with less need for rescue medication (p < 0.001). This suggests that oral tramadol/dexketoprofen provides more effective pain control in the immediate postoperative period after THA.

Unlock the Full ACE Report

You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now

Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics

Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics

Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions

Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics

Or upgrade today and gain access to all OrthoEvidence
content for as little as $1.99 per week.
0 of 4 monthly FREE articles unlocked
You've reached your limit of 4 free articles views this month

Access to OrthoEvidence for as little as $1.99 per week.

Stay connected with latest evidence. Cancel at any time.
  • Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
  • Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
  • Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Upgrade
Welcome Back!
Forgot Password?
Start your FREE trial today!

Account will be affiliated with


OR
Forgot Password?

OR
Please check your email

If an account exists with the provided email address, a password reset email will be sent to you. If you don't see an email, please check your spam or junk folder.

For further assistance, contact our support team.

Translate ACE Report

OrthoEvidence utilizes a third-party translation service to make content accessible in multiple languages. Please note that while every effort is made to ensure accuracy, translations may not always be perfect.

Cite this ACE Report

OrthoEvidence. Oral Tramadol/Dexketoprofen & Injectable Paracetamol + Tramadol: A Meta-Analysis. ACE Report. 2024;306(10):18. Available from: https://myorthoevidence.com/AceReport/Show/oral-tramadol-dexketoprofen-injectable-paracetamol-tramadol-a-meta-analysis

Copy Citation
Please login to enable this feature

To access this feature, you must be logged into an active OrthoEvidence account. Please log in or create a FREE trial account.

Premium Member Feature

To access this feature, you must be logged into a premium OrthoEvidence account.

Share this ACE Report